B
Bertrand Cariou
Researcher at University of Nantes
Publications - 364
Citations - 15769
Bertrand Cariou is an academic researcher from University of Nantes. The author has contributed to research in topics: Diabetes mellitus & Medicine. The author has an hindex of 56, co-authored 311 publications receiving 12634 citations. Previous affiliations of Bertrand Cariou include Centre national de la recherche scientifique & University of Burgundy.
Papers
More filters
Journal ArticleDOI
Role of Bile Acids and Bile Acid Receptors in Metabolic Regulation
TL;DR: Results suggest that modulation of FXR activity and BA metabolism may open new attractive pharmacological approaches for the treatment of the metabolic syndrome and type 2 diabetes.
Journal ArticleDOI
Phenotypic characteristics and prognosis of inpatients with COVID-19 and diabetes: the CORONADO study.
Bertrand Cariou,Samy Hadjadj,Matthieu Wargny,Matthieu Pichelin,Abdallah Al-Salameh,Ingrid Allix,Coralie Amadou,Gwénaëlle Arnault,Florence Baudoux,Bernard Bauduceau,Sophie Borot,Muriel Bourgeon-Ghittori,Olivier Bourron,David Boutoille,Claude Chaumeil,Emmanuel Cosson,Sandrine Coudol,Patrice Darmon,Emmanuel Disse,Amélie Ducet-Boiffard,Bénédicte Gaborit,Michael Joubert,Véronique Kerlan,Bruno Laviolle,Lucien Marchand,Laurent Meyer,Louis Potier,Gaëtan Prévost,Jean-Pierre Riveline,Jean-Pierre Riveline,René Robert,Pierre Jean Saulnier,Ariane Sultan,Jean François Thébaut,Charles Thivolet,Blandine Tramunt,Camille Vatier,Ronan Roussel,Jean François Gautier,Pierre Gourdy +39 more
TL;DR: BMI, but not long-term glucose control, was positively and independently associated with tracheal intubation and/or death within 7 days of admission in people with diabetes hospitalised for COVID-19.
Journal ArticleDOI
PCSK9 inhibition with evolocumab (AMG 145) in heterozygous familial hypercholesterolaemia (RUTHERFORD-2) : a randomised, double-blind, placebo-controlled trial
Frederick J. Raal,Evan A. Stein,Robert Dufour,Traci Turner,Fernando Civeira,Lesley J. Burgess,Gisle Langslet,Russell S. Scott,Anders G. Olsson,David R. Sullivan,G. Kees Hovingh,Bertrand Cariou,Ioanna Gouni-Berthold,Ransi Somaratne,Ian Bridges,Rob Scott,Scott M. Wasserman,Daniel Gaudet +17 more
TL;DR: In patients with heterozygous familial hypercholesterolaemia, evolocumab administered either 140 mg every 2 weeks or 420 mg monthly was well tolerated and yielded similar and rapid 60% reductions in LDL cholesterol compared with placebo.
Journal ArticleDOI
The Farnesoid X Receptor Modulates Adiposity and Peripheral Insulin Sensitivity in Mice
Bertrand Cariou,Bertrand Cariou,Bertrand Cariou,Kirsten Van Harmelen,Kirsten Van Harmelen,Kirsten Van Harmelen,Daniel Duran-Sandoval,Daniel Duran-Sandoval,Daniel Duran-Sandoval,Theo H. van Dijk,Aldo Grefhorst,Mouaadh Abdelkarim,Mouaadh Abdelkarim,Mouaadh Abdelkarim,Sandrine Caron,Sandrine Caron,Sandrine Caron,Gérard Torpier,Gérard Torpier,Gérard Torpier,Jean Charles Fruchart,Jean Charles Fruchart,Jean Charles Fruchart,Frank J. Gonzalez,Folkert Kuipers,Bart Staels,Bart Staels,Bart Staels +27 more
TL;DR: A novel role of FXR in the regulation of peripheral insulin sensitivity and adipocyte function is identified, which opens new perspectives for the treatment of type 2 diabetes.
Journal ArticleDOI
Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease
J-F Yale,George L. Bakris,Bertrand Cariou,Dennis K. Yue,Elias David-Neto,Liwen Xi,K. Figueroa,Ewa Wajs,Keith Usiskin,Gary Meininger +9 more
TL;DR: This study evaluated the efficacy and safety of canagliflozin in subjects with T2DM and stage 3 chronic kidney disease.